DIRS.INFO The most relevant business & tech news

Her patients inquire about testosterone therapy for multiple problems — to improve mood, energy, sex drive, brain fog and muscle mass. She tells patients that testosterone therapy is currently only recommended for a low sex drive, although future research may find other benefits. Shifren, who has been involved in clinical trials looking at testosterone therapy in women, said that the benefits for women with low libido aren’t terribly impressive. When men start testosterone therapy, it is typically given in a gel with a dose of 50-100 mg a day. Voedisch recalls one patient who finally stopped testosterone therapy after her voice was altered.

Persons: Dr, Rebecca Dunsmoor, Su, They’re, Amy Voedisch, Voedisch, ”, “, “ It’ll, they’ve, Traci Kurtzer, ” Kurtzer, Jan Shifren, Hospital’s, Shifren, It’s, Marcella Hill, Hill, ” Hill, didn’t, hadn’t, , Hill isn’t, ’ ” Organizations: OB, Stanford Medicine, Northwestern Medicine Center, Sexual, Drug Administration, Massachusetts, Health Locations: U.S, Palo Alto , California, Chicago, Boston, Vineyard , Utah

☆ Biotech stocks are an unappreciated way to profit from lower rates, Goldman says
▼ + stars: | 2024-09-18 | by ( Scott Schnipper | ) www.cnbc.com time to read: +3 min

Biotechnology stocks offer an under-the-radar and unappreciated way to profit from the central bank's looming campaign to start cutting the cost of borrowing, according to Goldman Sachs. Investors may have already begun to anticipate the effect of lower rates on some biotech companies. IBB .SPX mountain 2024-06-30 The iShares Biotechnology ETF has risen more than twice as much as the S & P 500 this quarter. The iShares Biotech ETF is up 7.7% this quarter while the Nasdaq Biotech Index has advanced 7.4%, more than double the 3.2% gain in the S & P 500 since June 30. Year-to-date, Regeneron is up 30.6% and Vertex by 18.3%, both outperforming the 18.1% rise in the S & P 500.

Persons: Goldman Sachs, John Flood, Goldman, Flood, Regeneron Organizations: Biotechnology, Federal Reserve, Gilead Sciences, Nasdaq Biotechnology, IQVIA Holdings, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals, iShares Biotech, Nasdaq Biotech Locations: Gilead

☆ Eli Lilly reports earnings Thursday. Here's what Wall Street is watching
▼ + stars: | 2024-08-07 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +5 min

Novo Nordisk shocked investors on Wednesday when its latest results fell short of Wall Street's expectations. While Eli Lilly's stock remains up about 32% year to date, concerns about increasing competition in the category have resulted in a nearly 16% decline for Lilly shares over the past month. Eli Lilly is making similar attempts with Zepbound, but its launch is at an earlier stage than Wegovy. Second-quarter sales of Ozempic, Novo's diabetes treatment, rose 4% from the first quarter, while Wegovy revenue grew 24% quarter over quarter. Barclays analyst Emily Field told clients in a research note that she would be a buyer of Novo Nordisk shares on the weakness.

Persons: Eli Lilly, Eli, Lilly, Wells, Mohit Bansal, Ozempic, Bansal, Emily Field, David Song, Song, Chris Schott, Schott Organizations: Novo Nordisk, LSEG, Lilly's, Management, Food and Drug Administration, Barclays, Tema, JPMorgan Locations: Wells Fargo, IQVIA, Amgen, MariTide, Novo, CagriSema

☆ This health-care stock just broke out higher and shows little signs of slowing down, according to charts
▼ + stars: | 2024-07-22 | by ( Katie Stockton | ) www.cnbc.com time to read: +2 min

During earnings season, we can gain value from the charts by judging how stocks react to their reports. We are especially mindful of support and resistance levels, watching for breakouts and breakdowns as technical catalysts. This supports upside follow-through for IQV in the weeks ahead towards resistance from a Fibonacci retracement level near $258. We ultimately expect the stock to retest final resistance, near $285, with a long-term time horizon. Long-term support on the chart is defined by the weekly cloud model, which rises to roughly $215 next month.

Persons: Katie Stockton, Will Tamplin Organizations: IQVIA Holdings, IQV, CNBC, NBC UNIVERSAL Locations: IQV

☆ Stocks making the biggest moves midday: Ryanair, CrowdStrike, IQVIA Holdings and more
▼ + stars: | 2024-07-22 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

Check out the companies making headlines in midday trading: Ryanair — Shares fell 16% after the budget airline reported weaker-than-expected fiscal first-quarter earnings . CrowdStrike — The cybersecurity stock plunged 12% as investors fully digested Friday's massive outage , which resulted in thousands of canceled flights. IQVIA Holdings — The stock jumped more than 6% after the health tech company's earnings beat expectations for the second quarter. In the second quarter, the company reported sales of $32.8 billion, below the $33.05 billion FactSet consensus estimate. Mattel — Shares of the toymaker soared more than 11%.

Persons: CrowdStrike, FactSet, Tesla, Elon Musk, LPR, Xpeng, Catterton, —, Alex Harring, Hakyung Kim, Lisa Kailai Han, Darla Mercado Organizations: Ryanair —, Guggenheim, Holdings, Nvidia —, Reuters, Blackwell, Verizon —, —, EV, People's Bank of, Li Auto, Mattel —, Mattel, Semiconductor, — Investors, VanEck Semiconductor, KLA Corporation, ASML Locations: CrowdStrike, People's Bank of China, chipmakers

☆ Alphabet earnings and 3 more things we're watching in the stock market next week
▼ + stars: | 2024-07-20 | by ( Zev Fima | ) www.cnbc.com time to read: +12 min

But in general, this is the kind of development we've hoped to see ever since Starbucks' massive earnings miss April 30. We'll take the nearly 7% pop in shares Friday and hope it's only the beginning of recovery for the beaten-up stock. Fed's fave inflation measure : The personal spending and income report will be the most closely watched economic report next week. Earnings : As the second-quarter earnings season picks up pace, we'll hear from five Club holdings next week including Google parent Alphabet . Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Russell, Donald Trump, — Trump, Jim Cramer, Trump, Donald Trump's, Taiwan's TSMC, Joe Biden's, Biden, Biden's, he's, Elliott, we've, We'll, it's, we'll, Sartorius, Ford, Jim Farley, We're, Honeywell management's, —, Zions, BOK, Brown, BRO, Lockheed Martin, Philip Morris, Clark, Lamb, Edwards Lifesciences, DOV, Dr Pepper, CARR, Baker Hughes, Booz Allen Hamilton, Jim Cramer's, Jim Organizations: Federal Reserve, Nasdaq, Dow, Republican National Convention, GOP, Bloomberg Businessweek, Trump, Elliott Management, Starbucks, Street Journal, Technology, General Motors, Honeywell, Dover, Products Company, Verizon, Truist, SAP, Semiconductors, Crown Holdings, Cadence Design Systems, Medpace Holdings, AGNC Investment, Logitech International S.A, KKR Real Estate Finance Trust, Berkley Corp, Spotify Technology S.A, United Parcel Service, GE Aerospace, GE, Cola Company, Lockheed, Comcast, Polaris Industries, Philip Morris International, Company, HCA Healthcare, Moody's Corporation, Enphase Energy, Texas Instruments Incorporated, Chubb Corporation, Seagate Technology plc, Maine, Packaging Corporation of America, Weatherford International plc, Canadian National Railway Company, FTAI Aviation Ltd, Mattel, Vertiv Holdings Co, Lamb Weston Holdings, NextEra Energy, Tenet Healthcare, Fisher, GE Vernova, Boston Scientific Corporation, General Dynamics, Lennox International, Software Technologies, CME Group, Fortive Corporation, Co, Roper Technologies, Teck Resources Limited, Blackstone Mortgage Trust, Economico Mexicano S.A, Dominion Freight, Otis Worldwide Corporation, OTIS, Ford Motor Company, Grill, Business Machines, IBM, Viking Therapeutics, Las Vegas Sands Corp, Newmont, Whirlpool, Globe, WM, O'Reilly Automotive, Annaly Capital Management, Honeywell International, American Airlines Group, Hasbro, Southwest Airlines Co, New York Community Bancorp, RTX Corporation, AstraZeneca, Carrier Global Corporation, Integer Holdings Corporation, Valero Energy, Texas, Juniper Networks, Boston Beer Company, Physicians Realty Trust, Allison Transmission Holdings, Corp, Columbia Banking, Digital Realty Trust, Edison International, Myers Squibb, Charter Communications, 3M Company, Booz, Centene Corporation, AON, Barnes, Colgate, Palmolive, Jim Cramer's Charitable, CNBC, U.S Locations: U.S, Taiwan, FactSet, China, Dover, Cleveland, Alexandria, ZION, W.R, Freeport, Kimberly, Cal, Teck, Las, ORLY, New, Banc, Bristol, Milwaukee , Wisconsin

☆ Final Trades: Amazon, Goldman Sachs, AbbVie and IQVIA Holdings
▼ + stars: | 2024-06-06 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFinal Trades: Amazon, Goldman Sachs, AbbVie and IQVIA HoldingsThe Investment Committee give you their top stocks to watch for the second half.

Persons: Goldman Sachs Organizations: IQVIA Holdings, Investment

☆ Why Eli Lilly's earnings are no sure thing for traders despite obesity drug momentum
▼ + stars: | 2024-04-29 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +5 min

Tirzepatide is the active ingredient in both Eli Lilly's diabetes treatment Mounjaro and its anti-obesity drug Zepbound. Based on that calculation, earnings will be lower by about 13 cents per share, he said, in research published last Tuesday. "Strong demand for Mounjaro & Zepbound can easily pull through in 2H24 and make up for any 1H24 shortfalls." For the week ended April 19, combined prescriptions of Mounjaro and Zepbound rose 63% year over year, according to IQVIA. Wells Fargo Mohit Bansal said he expects investors to look past any Trulicity shortfalls as the focus is firmily on Zepbound and Mounjaro for Lilly's future growth.

Persons: Eli Lilly, Eli, James Shin, Lilly, Shin, David Risinger, Zepbound, Wells, Bansal, Jo Walton, Walton, Lilly's, Tirzepatide, Deutsche Bank's Shin, — CNBC's Michael Bloom Organizations: Drug Administration, Deutsche Bank, IMS, UBS, Research, Deutsche, FDA Locations: 2H24, U.S

☆ Viking stock doubled Tuesday. Here's where the next moves in the obesity space could come from
▼ + stars: | 2024-02-27 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +8 min

VKTX YTD mountain Viking shares year to date Then, Viking shares more than doubled in trading on Tuesday, putting the stock on pace to report a more than 300% year-to-date gain, after the company said its GLP-1/GIP receptor agonist VK2735 hit all its primary goals in a phase 2 clinical trial. The Tema Cardiovascular and Metabolic ETF (HRTS) , which is up 12% year to date, owns Novo, Lilly and Viking. Still early days Some analysts and investors admit it is still very early days for obesity treatment and many questions remain to be answered. "We continue to expect above consensus growth in the space, as we are bullish on adoption from payers and broader obesity uptake," Meacham wrote. For obesity only, Lilly has already gained a 38% share, despite only being in the market for 13 weeks, he said.

Persons: Eli Lilly, Geoff Meacham, Meacham, Lilly, Yuri Khodjamirian, Khodjamirian, Jeff Jonas, Becton Dickinson, Novo, BofA's Meacham, What's, Tema's, it's, Gabelli's Jonas, he's, William Blair, Andy Hsieh, Hsieh Organizations: Novo Nordisk, Bank of America, Centers for Disease Control, Zealand Pharma, Viking Therapeutics, Zealand, Food and Drug Administration, Novo, Metabolic, Therapeutics, Pharmaceuticals, Rock, AstraZeneca, Roche, Gabelli Funds, FDA, Viking, Merck, Pfizer Locations: U.S, Tema, Novo Nordisk's, GLP, Lilly

☆ Antidepressant prescriptions to youths spiked during pandemic, study finds
▼ + stars: | 2024-02-26 | by ( Kristen Rogers | ) edition.cnn.com time to read: +7 min

CNN —Many young people have reported having poor mental health during and after the Covid-19 pandemic. Their experiences are affirmed by a new study finding that the rate of prescribing antidepressants to this group also spiked during the same period. But since the Covid-19 outbreak in the United States in March 2020, the dispensing rate rose nearly 64% faster than normal, according to the study published Monday in the journal Pediatrics. In female adolescents ages 12 to 17, the dispensing rate increased 130% faster after March 2020, Chua said. “I can’t tell you how many pediatricians have told me that they feel like they’re just mental health clinicians at this point,” he said.

Persons: . Kao, Ping Chua, Chua, ” Chua, ”, “, Neha Chaudhary, wasn’t, ” Chaudhary, don’t, Chaudhary, “ Young Organizations: CNN, Pediatrics, University of Michigan’s School of Public Health, Massachusetts General Hospital, Modern Health, Food and Drug Administration Locations: United States, Massachusetts, “

☆ Stocks making the biggest moves midday: Uber, Airbnb, MGM Resorts, Robinhood and more
▼ + stars: | 2024-02-14 | by ( Tanaya Macheel | ) www.cnbc.com time to read: +5 min

Uber — Uber's shares jumped 11%, climbing to a new 52-week high, after the ride-hailing company announced an inaugural $7 billion share repurchase authorization program. The higher end of the company's full-year earnings per share guidance, $11.40, was also above estimates of $10.83 per share. On Tuesday, DaVita posted earnings of $1.87 per share, ex-items, on $3.15 billion in revenue. Robinhood Markets — Shares of the trading platform jumped 9% after the company posted a surprise earnings and revenue beat. Robinhood posted earnings of 3 cents per share, while analysts expected a 1 cent per share loss, according to LSEG.

Persons: Uber, Uber's, Lyft, IQVIA, Charles River, DaVita, FactSet, Robinhood, Zillow, LSEG, bitcoin, Energy rocketed, CleanSpark, Topgolf Callaway, Akamai, Kraft Heinz, Airbnb, CNBC's Hakyung Kim, Alex Harring, Jesse Pound, Pia Singh, Michelle Fox Organizations: Uber Technologies, Inc, IQVIA Holdings, Charles River Laboratories, Revenue, Miners, Energy, Marathon, MGM Resorts, Hasbro Locations: New York City, FactSet, LSEG, China, Macau, U.S, Detroit

☆ Eli Lilly's Zepbound is off to a strong start, but here's what needs to happen to push shares higher
▼ + stars: | 2024-01-24 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +8 min

Lilly's Mounjaro and Zepbound both use tirzepatide as an active ingredient, but Mounjaro is indicated for type 2 diabetes, while Zepbound aids weight loss. A rich valuation LLY 1Y mountain Eli Lilly shares over the past year. But even good news about Zepbound's launch might not be enough to propel Lilly's stock higher. Goldman's Shibutani has a neutral rating on Lilly shares and a price targe of $600, which implies shares could fall nearly 5% from they started the week. He has a buy rating on Lilly shares, and expects the stock could hit $700 over the next 12 months.

Persons: Eli Lilly's, Lilly, Goldman Sachs, Chris Shibutani, IQVIA, Shibutani, Lilly's, Mounjaro, Eli Lilly, Geoff Meacham, NASH, Meacham, there's, Morgan Stanley, Terence Flynn, Flynn, Morgan Stanley's, Michael Bloom Organizations: Food and Drug Administration, Zepbound, Novo Nordisk's, Medicare, Bank of America, Novo Nordisk, Bank of, FDA, CNBC Locations: Indianapolis, Mounjaro

☆ GSK CEO says RSV vaccine revenue to top 1 bln pounds in first year
▼ + stars: | 2023-11-30 | by ( Michele Gershberg | ) www.reuters.com time to read: +4 min

GSK had previously forecast 2023 sales for Arexvy between 900 million pounds and 1 billion pounds ($1.26 billion) following a strong U.S. launch. "We’re delighted with the start of our RSV vaccine," Walmsley said in a Reuters Newsmaker interview. The U.S. Food and Drug Administration (FDA) approved Arexvy for adults aged 60 years or older in May and GSK launched the vaccine in the U.S. later in the year. GSK made close to two-thirds of RSV doses given in the United States since early September, according to IQVIA data earlier this month. On Tuesday, rival Pfizer (PFE.N) said it was disappointed in the performance of its RSV shot Abrysvo compared with GSK.

Persons: Walmsley, GSK's, Emma Walmsley, We’re, David Denton, AstraZeneca's, commercialise Johnson, Ludwig Burger, Michael Erman, Josephine Mason, Kirsten Donovan, Elaine Hardcastle Organizations: GSK, Reuters, U.S . Food, Drug Administration, Pfizer, U.S, Thomson Locations: British, U.S, Europe, Japan, United States

☆ GSK lifts annual forecasts on strong launch of RSV vaccine
▼ + stars: | 2023-11-01 | by ( Eva Mathews | ) www.reuters.com time to read: +3 min

Arexvy, launched in the United States recently, recorded third quarter sales of 709 million pounds ($862 million), trouncing analysts' expectations of 358 million pounds, according to a company-compiled consensus. GSK accounts for close to two-thirds of RSV shots given in the United States since early September, according to IQVIA data. Full-year sales are seen between 900 million pounds and 1 billion pounds for the shot, GSK said. The company faces about 79,000 cases related to Zantac in the United States, with 73,000 of them in Delaware and scheduled for trial starting January 2024. For the third quarter, Shingrix, the company's top-selling drug for shingles, generated 825 million pounds in sales.

Persons: Dado Ruvic, Abrysvo, Dani Saurymper, Emma Walmsley, Eva Mathews, Maggie Fick, Tomasz Janowski, Mark Potter Organizations: GSK, GlaxoSmithKline, REUTERS, stg, CVS, Pfizer, Pacific Asset Management, GSK's, Thomson Locations: London, United States, U.S, Europe, Japan, Delaware, Bengaluru

☆ IQVIA cuts annual profit forecast on slow demand for medtech, analytics services
▼ + stars: | 2023-11-01 | by ( ) www.reuters.com time to read: +2 min

Nov 1 (Reuters) - IQVIA Holdings (IQV.N) cut its full-year profit forecast on Wednesday, citing weakness in demand for its analytics and medical technology solutions along with the impact of a stronger U.S. dollar. Thermo Fisher signaled that the demand slump from biotech clients for its contract research services could extend into the next year due to rising interest rates and a persistent funding crunch. On an adjusted basis, IQVIA reported a profit of $2.49 per share for the third quarter, topping estimates of $2.44 per share. The company now expects full-year adjusted profit to be between $10.16 and $10.23 per share, compared with its prior per-share forecast of $10.26 to $10.56. IQVIA now expects 2023 revenue between $14.89 billion and $14.92 billion, compared with its previous forecast of $15.05 billion to $15.18 billion.

Persons: IQVIA, Fisher, Christy Santhosh, Shweta Agarwal Organizations: IQVIA Holdings, Danaher Corp, Thomson Locations: Durham , North Carolina, Bengaluru

☆ Pfizer RSV vaccine lags GSK’s as head-to-head competition underway
▼ + stars: | 2023-10-30 | by ( Michael Erman | ) www.reuters.com time to read: +4 min

[1/3] View of Pfizer's new respiratory syncytial virus (RSV) vaccine Abrysvo during its manufacture in this undated handout picture. "800 POUND GORILLAS"CVS, which has more than 9,000 U.S. locations, declined to comment on why it was only carrying GSK's vaccine. It was not immediately clear how many RSV shots were being administered in pharmacies versus doctors' offices. GSK declined to discuss its RSV vaccine contracts, but said customer relationships gives it a competitive advantage. Two independent pharmacists said they are being charged a lower price by wholesalers for the GSK vaccine, which comes in boxes of 10.

Persons: Price, Ben Link, Link, Pfizer's, Dovato, Morningstar, Damien Conover, We’ve, Alison Hunt, Michelle Vargas, Michael Erman, Caroline Humer, Bill Berkrot Organizations: Pfizer, Handout, REUTERS, GSK, Reuters, CVS Health, CVS, Walgreens, Walmart, Aid, Thomson Locations: United States, British, U.S, South Carolina

☆ Starboard may be poised to build value amicably at contract research firm Fortrea
▼ + stars: | 2023-10-21 | by ( Kenneth Squire | ) www.cnbc.com time to read: +5 min

CROs work with drug companies through all stages of the drug development process, from drug discovery and preclinical development to Phase I through IV post-approval work. With a material portion of that outsourced, the CRO industry has grown accordingly. So, there are strong secular tailwinds driving growth for the CRO industry, but to be a successful contract research organization, it helps to have global scale. With peer margins and peer multiples, Starboard sees this as a $47 to $72 stock. Elliott Management recently partnered with Patient Square Capital and Veritas Capital to acquire Fortrea peer Syneos Health Inc (SYNH) for $7.1 billion.

Persons: Covance, Fortrea, Tom Pike, Pike, Elliott, Ken Squire Organizations: Fortrea, Labcorp, Development, Elliott Management, Square, Veritas Capital, Inc, pharma, 13D, Fortrea Holdings Locations: Covance, Labcorp, Fortrea

☆ Pro Take: Making Medicines Greener
▼ + stars: | 2023-10-19 | by ( Cecilia Butini | ) www.wsj.com time to read: +6 min

Photo: mohamed hossam/ShutterstockMaking and supplying medicines generates roughly a third of the global healthcare industry’s greenhouse-gas emissions. Photo: Carlos Jasso/Bloomberg NewsBritish drugmaker GSK , for instance, plans to run on 100% renewable electricity by 2025 and to reach net-zero emissions across its value chain by 2045. GSK partnered with AstraZeneca , Merck KGaA, Novo Nordisk , Roche Holding , Samsung Biologics and Sanofi to form the SMI Health Systems Task Force in 2021. Last year, the partnership decided to strengthen their collaboration by focusing on cutting emissions in the near term and transitioning faster toward net-zero health systems. Novartis aims to achieve net-zero emissions across its value chain by 2040.

Persons: mohamed hossam, Carlos Jasso, “ We’ve, ”, Mike Peirce, Aurelio Arias, Arias, Claire Lund, Sanofi, Annabelle Harreguy, IQVIA’s Arias, “ It’s, ” Arias, Cecilia Butini Organizations: Pharmaceutical, Pharma, GSK, Bloomberg News British, Climate Group, Climate, Business, Sustainable Markets, Health Systems, Force, AstraZeneca, Merck KGaA, Novo Nordisk, Roche Holding, Samsung Biologics, Sanofi, SMI, Systems, Novartis, World Health Organization, cecilia.butini@wsj.com Locations: GSK’s, China, India, Novo

☆ Analysts predicted new obesity medicines would be blockbusters. Now they’re raising their forecasts
▼ + stars: | 2023-09-16 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +9 min

Fernandez sees a total addressable market of $140 billion to support patients with obesity. He expects there is a potential for GLP-1 drugs to become as common and widely used, much like statins are used to lower cholesterol. Morgan Stanley's Flynn estimates a 30% share of the diabetes market would generate $109 billion on a worldwide basis for GLP-1 drugs. Layer in a 15% to 30% share of the obesity market and that equates to worldwide sales of $97.4 billion to $194.8 billion. Guggenheim's estimates also assume that oral GLP-1 drugs that are currently in development are able to come to market a few years from now.

Persons: Seamus Fernandez, Fernandez, Lilly, Eli Lilly, Morgan Stanley, Terence Flynn, Eli Lilly's Mounjaro, Insulet, Canaccord, William Plovanic, Plovanic, It's, Morgan Stanley's Flynn, Flynn, Novo, Michael Bloom Organizations: Wall, Novo, American Heart Association, Food and Drug Administration, Novo Nordisk, Iqvia, Disease Control Locations: GLP

☆ Insight: What happens when a $2 million gene therapy is not enough
▼ + stars: | 2023-08-12 | by ( Deena Beasley | ) www.reuters.com time to read: +13 min

Their experience raises broader questions around other high-cost gene therapies coming to market, sometimes after accelerated regulatory approvals, drug pricing experts said. Gene therapies work by replacing genes – the body's blueprint for its development. The gene Zolgensma delivers instructs the body to make a protein vital for muscle control. If gene therapies do fall short, it becomes harder to justify prices that researchers have argued are already poor value. More recently, the first hemophilia gene therapy approved by the U.S. Food and Drug Administration was priced by CSL Behring at $3.5 million; 26 more gene therapies are in late-stage development, according to IQVIA.

Persons: Elizabeth Kutschke, Ben, Zolgensma, Ben Kutschke, neurologists, Sitra Tauscher, Wisniewski, Ben's, Roger Hajjar, Brigham Gene, Kutschke, Vasant Narasimhan, Stacie Dusetzina, Roche's, Biogen, Roche, Maha Radhakrishnan, Steven Pearson, It's, Sree Chaguturu, Amanda Cook, Weston, Jackson, Cook, Elizabeth, Jerry Mendell, Russell Butterfield, –, Biogen's, Mendell, UMR, Spinraza, Eric Cox, Caroline Humer, Sara Ledwith Organizations: Reuters, U.S, Novartis, IQVIA Institute, Human Data, Novartis Gene Therapies, Mass, Cell Therapy, U.S . Food, Drug Administration, CSL Behring, CSL, Nashville's Vanderbilt University School of Medicine, Clinical, Economic, CVS Health, Aetna, SMA, Nationwide Children's Hospital, University of Utah Health, Children's, UnitedHealth, Thomson Locations: Oak Park, Berwyn , Illinois, Swiss, U.S, Lebanon , Virginia, United States, Columbus , Ohio, Russia, Kazakhstan, Chicago

☆ IQVIA cuts annual profit forecast on soft demand for healthcare tech services
▼ + stars: | 2023-08-01 | by ( ) www.reuters.com time to read: +1 min

Aug 1 (Reuters) - Contract research firm IQVIA Holdings (IQV.N) cut its annual profit and revenue forecasts on Tuesday, on expectations of slower demand from clients for its healthcare data and analytics services. Analysts were expecting annual profit of $10.39 per share, according to Refinitiv. The company, however, reported better-than-expected second-quarter profit and revenue, on the back of strong demand for its drug research and development services. It reported revenue of $3.73 billion for the quarter ended June 30, slightly above analysts' average estimate of $3.71 billion. Excluding one-off items, IQVIA reported a profit of $2.43 per share for the second quarter, above analysts' average estimate of $2.37 per share.

Persons: Ari Bousbib, IQVIA, Pratik Jain, Krishna Chandra Organizations: IQVIA Holdings, Technology, Analytics Solutions, Thomson Locations: The Durham , North Carolina, Bengaluru

☆ Morning Bid: August cools Wall St stocks
▼ + stars: | 2023-08-01 | by ( ) www.reuters.com time to read: +4 min

China's factory underperformance stood out once again and underlined its struggling recovery - perhaps the main driver of stalling industrial activity everywhere. With markets increasingly impatient at the patchy and underwhelming economic stimulus plans seen from Beijing so far, China stocks fell back (.CSI300), bucking Tuesday's wider Asia stocks rally. Sterling and UK stocks (.FTMC) fell back. Ride-hailing giant Uber's stock rose more than 2% before the bell and ahead of its earnings report. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.

Persons: Mike Dolan, underperformance, Austan Goolsbee, Goolbee, Stanley Black, Decker, Zimmer Biomet, Revvity, Bernadette Baum Organizations: Federal Reserve, U.S ., Chicago Fed, Bank of England, Sterling, AMD, Caterpillar, Big Pharma, Pfizer, Merck, Ride, HSBC, BP, Uber, Prudential Financial, AIG, Starbucks, Molson Coors, Boston Properties, Caesars Entertainment, Illinois Tool, Natural Resources, Energy, Devon Energy, Gartner, Allstate, Paycom Software, Electronic, WEC, Rockwell, Public Service Enterprise, P Global, Dallas Fed, Chicago Federal, Reuters Graphics Reuters, Reuters, Thomson Locations: U.S, Wall, Beijing, China, Asia, ., Marathon, Eaton, Altria, Marriott, Illinois, Progressive

☆ On tap this week: Jobs report plus 10 key earnings. Here's what we want to see
▼ + stars: | 2023-07-29 | by ( Zev Fima | ) www.cnbc.com time to read: +18 min

All three major averages advanced for the week, powered by strong mega-cap earnings and favorable inflation data. Looking to next week, earnings season enters its second half with the last of our mega-caps — Apple (AAPL) and Amazon (AMZN) — set to report on Thursday. We'll get a better read on the employment picture on Wednesday with the ADP report and then, more importantly, on Friday's nonfarm payrolls report for July. Thursday after the close brings us to the main events of the week: Earnings from Apple and Amazon. For those looking to review first quarter performance ahead of these releases, be sure to keep our first-quarter earnings report card handy.

Persons: We'll, that's, Stanley Black, Decker, Emerson, Bausch, Leggett, Platt, SIRI, Ares, COLM, PERI, Kraft Heinz, Phillips, Ferrari N.V, Johnson, Robinson, COOK, BUD, Kellogg, Papa, Pitney Bowes, Parker, Trimble, Ziff Davis, Nonfarm, Jim Cramer's, Jim Cramer, Jim, Apple Tim Cook, Kevin Dietsch Organizations: Nasdaq, Dow, Federal Reserve, Federal, ISM Manufacturing, Services PMI, Investors, Caterpillar, Devices, Starbucks, Natural Resources, AMD, Management, Emerson Electric and, Humana, Bausch Health, Apple, Microsoft, Resource Partners, AerCap Holdings, CNA Financial Corp, CNA, Apellis Pharmaceuticals, Bank, SJW, Hutchison China MediTech, Camtek Ltd, Silvercrest Asset Management, Loews Corp, Oxford Lane Capital Corp, Banco Santander, Silicom Ltd, SuperCom Ltd, Arista Networks, Avis Budget Group, Diamondback Energy, Lattice Semiconductor Corp, Republic Services, Yum China Holdings, Western Digital Corp, Power Systems, Tenet Healthcare Corp, Vornado Realty, BioMarin Pharmaceutical, PetMed, SBA Communications Corporation, Brixmor, Snack Foods Corp, Cushman & Wakefield, Sanmina Corporation, TFI, PMI, Cruise Line Holdings Ltd, Uber Technologies, Pfizer, Enterprise Products Partners, Merck, JetBlue Airways Corporation, Allegro MicroSystems, Altria, SunPower Corp, SiriusXM Holdings, Molson Coors Beverage, Marriott International, Toyota Motor Corp, BP, SYSCO Corp, Marathon Petroleum Corp, Ares Management, Equitrans Midstream Corporation, Game Technology, Illinois Tool, IDEXX Laboratories, Rockwell Automation, Packaging International Corp, Gartner, Zebra Technologies Corp, IQVIA Holdings, Oshkosh Corporation, Leidos Holdings, Eaton Corp, yte Corp, Lear Corp, Starbucks Corp, Devon Energy Corp, SolarEdge Technologies, Lumen Technologies, Virgin Galactic Holdings, Caesars Entertainment, VF Corp, Sciences Corp, Paycom, Vertex Pharmaceuticals, Suncor Energy, Holdings, Chesapeake Energy Corp, Boston Properties, American International Group, AIG, Allstate Corp, Aspen Technology, Electronic Arts, EA, Flowserve Corporation, Denny's, Corp, Prudential Financial, Store, Ternium S.A, Vimeo, Emerson, Lomb, CVS Health, Generac Holdings, Cameco Corp, Perion Network Ltd, Builders, Carlyle Group, Scorpio, Teva Pharmaceutical Industries, Ltd, Rithm Capital Corp, AeroSystems Holdings, Vertiv Holdings Co, Johnson Controls, CDW Corp, DuPont, Brands Holdings, Scotts Miracle, Gro, SMG, Brands, Allegheny Technologies, AmerisourceBergen Corporation, ABC, Real Estate Corporation, Adient plc, Editas, Garmin Ltd, WWE, Bunge Ltd, Criteo S.A, PayPal, QUALCOMM, Occidental Petroleum Corp, Apache Corp, Albemarle Corp, MGM Resorts International, MGM, Marathon Oil Corp, Joby Aviation, Industrial, CF Industries Holdings, Goodyear Tire &, Realty ome Corp, Metlife, Pacific Biosciences of, Rush Street Interactive, Zillow, JFrog Ltd, Herbalife Nutrition Ltd, Simon Property Group, McKesson Corp, Storage, Cerus Corporation, GXO Logistics, MAX Holdings, Health, Anheuser, Busch InBev, Warner Bros ., Cheniere Energy, ConocoPhillips, Hasbro, CIGNA Corp, Lantheus Holdings, Regeneron Pharmaceuticals, Fiverr International, Air Products & Chemicals, TopBuild Corp, EPAM Systems, Lightspeed Commerce, Aurinia Pharmaceuticals, Cummins, CMI, Slair Corporation, Starwood Property Trust, Vulcan, Alnylam Pharmaceuticals, New Energy Corp, Cedar Fair Entertainment, Intellia Therapeutics, Lending, Privia Health, Dickinson, Chimera Investment, CIM, Hyatt Hotels Corp, Lion Electric, LEV, Deluxe Corp, Murphy Oil Corp, PBF Energy, Papa John's, Targa Resources Corp, Wix.com Ltd, Apollo Global Management, LLC, Butterfly, Sempra Energy, Aptiv PLC, Brookfield Infrastructure Partners, Canada Goose Holdings, Hannifin Corporation, WESCO International, WCC, Arrow Electronics, Constellation Energy Group, Midstream Partners, Coinbase, Petroleo Brasileiro SA Petrobras, Gilead Sciences, Opendoor Technologies, Booking Holdings, Atlassian Corporation, International, Redfin Corporation, Motorola Solutions, Monster Beverage Corporation, Consolidated Edison, Rocket Companies, Apple Hospitality, Cirrus, Resources, Universal Display Corporation, Chesapeake Utilities Corp, Social, Defense, Security Solutions, Post Holdings, Tandem Diabetes Care, Nikola Corporation, Magna International, Dominion Energy, ACM Research, Frontier Communications, Brookfield Renewable Partners, inTEST Corporation, American Pipeline, TELUS International, XPO Logistics, Fluor Corp, Gray Television, Cboe, LyondellBasell Industries, Twist Bioscience, Global, Jim Cramer's Charitable, CNBC, Allen & Company Sun Valley, Getty Locations: U.S, China, India, Oxford, Chile, Illinois, Columbia, Pacific, Pacific Biosciences of California, Southern, PBI, Gilead, Sun Valley , Idaho

☆ Final Trades: SLB, Organon, IQVIA & more
▼ + stars: | 2023-07-14 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFinal Trades: SLB, Organon, IQVIA & moreThe "Halftime Report" traders give their top picks to watch for the second half.

Recessions haven't always resulted in declining stock markets, and good opportunities can be found amid them. Sectors for recession naysayersThe best sectors for recession disbelievers are the most economically sensitive ones: industrials, materials and financials. Well-positioned companies with good growth prospects currently include: Corteva, Dow Chemical, Ecolab, Linde plc, Martin Marietta Materials, Nucor Corp., PPG Industries and Sherwin-Williams. Currently buyable names include: Campbell Soup Co., General Mills, The Hershey Co., Kellogg's, Kimberly-Clark Corp., Kroger, Procter & Gamble and Walmart. Sector names with reasonable risk levels and good growth prospects include: Vertex Pharmaceuticals, IDEXX Laboratories, DaVita Inc., Veeva Systems Inc., IQVIA Holdings Inc., Cigna Group and Zoetis Inc.

Persons: Sherwin, Williams, Mayur, Martin Marietta, JPMorgan Chase, Rowe Price, Willis Towers Watson, Campbell, General Mills, Clark, Willie B, Thomas, Digitalvision Organizations: Westend61, University of Michigan Consumer, Investors, Westinghouse Air Brake Co, Cummins Inc, CSX, Emerson Electric, Otis Worldwide, Carrier, Caterpillar, Honeywell, Illinois Tool, Lockheed Martin Corp, Dow Chemical, Ecolab, Linde plc, Martin, Martin Marietta Materials, Nucor Corp, PPG Industries, XLF, JPMorgan, Rowe Price Group Inc, American International Group, Allstate, The, McLennan, Sectors, Co, Hershey Co, Clark Corp, Kroger, Procter, Gamble, Walmart, Getty Images Health, iShares U.S, Medical Devices, Vertex Pharmaceuticals, IDEXX Laboratories, DaVita Inc, Veeva Systems Inc, IQVIA Holdings Inc, Cigna, Zoetis Inc Locations: American, The Hartford, Marsh, Kimberly

Search resuls for: "Iqvia"

25 mentions found